| Literature DB >> 25568183 |
Yuan Hong1, Indumathi Manoharan1, Amol Suryawanshi1, Tanmay Majumdar1, Melinda L Angus-Hill2, Pandelakis A Koni1,3, Balaji Manicassamy4, Andrew L Mellor1,3, David H Munn1,5, Santhakumar Manicassamy1,3.
Abstract
Tumors actively suppress antitumor immunity, creating formidable barriers to successful cancer immunotherapy. The molecular mechanisms underlying tumor-induced immune tolerance are largely unknown. In the present study, we show that dendritic cells (DC) in the tumor microenvironment acquire the ability to metabolize vitamin A to produce retinoic acid (RA), which drives regulatory T-cell responses and immune tolerance. Tolerogenic responses were dependent on induction of vitamin A-metabolizing enzymes via the β-catenin/T-cell factor (TCF) pathway in DCs. Consistent with this observation, DC-specific deletion of β-catenin in mice markedly reduced regulatory T-cell responses and delayed melanoma growth. Pharmacologic inhibition of either vitamin A-metabolizing enzymes or the β-catenin/TCF4 pathway in vivo had similar effects on tumor growth and regulatory T-cell responses. Hence, β-catenin/TCF4 signaling induces local regulatory DC and regulatory T-cell phenotypes via the RA pathway, identifying this pathway as an important target for anticancer immunotherapy. ©2015 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25568183 PMCID: PMC4333068 DOI: 10.1158/0008-5472.CAN-14-2377
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701